Reproduction of the Cancer Genome Atlas (TCGA) and Asian Cancer Research Group (ACRG) Gastric Cancer Molecular Classifications and Their Association with Clinicopathological Characteristics and Overall Survival in Moroccan Patients
Table 2
Clinicopathological features related to the ACRG subtypes.
Variable
(%)
MSI ()
MSS/EMT ()
MSS/p53- ()
MSS/p53+ ()
value
Gender
0.917
-Male
59 (60.8%)
7 (53.8)
17 (58.6)
21 (63.6)
14 (63.6)
-Female
38 (39.2%)
6 (46.2)
12 (41.4)
12 (36.4)
8 (36.4)
Mean age at diagnosis (range)
59 (28-85)
59 (36-85)
55 (28-76)
60 (39-80)
64 (39-82)
0.101
Age at diagnosis
0.245
-≥50 years
80 (82.5)
9 (69.2)
22 (75.9)
29 (87.9)
20 (90.9)
-<50 years
17 (17.5)
4 (30.8)
7 (24.1)
4 (12.1)
2 (9.1)
History of gastrectomy
0.023
-Yes
7 (7.2)
0 (0)
4 (13.8)
0 (0)
3 (13.6)
-No
90 (92.8)
13 (100)
25 (86.2)
33 (100)
19 (86.4)
History of gastric ulcer
0.222
-Yes
3 (3.1)
0 (0)
0 (0)
1 (3)
2 (9.1)
-No
94 (96.9)
13 (100)
29 (100)
32 (97)
20 (90.9)
Tobacco smoking
0.207
-Yes
25 (25.8)
1 (7.7)
6 (20.7)
11 (33.3)
7 (31.8)
-No
72 (74.2)
12 (92.3)
23 (79.3)
22 (66.7)
15 (68.2)
Tumor location
0.156
-Cardia
31 (31.9)
4 (30.8)
11 (37.9)
13 (39.4)
3 (13.6)
-Noncardia
66 (68.1)
9 (69.2)
18 (62.1)
20 (60.6)
19 (86.4)
Tumor cells differentiation
0.079
-Well/moderate
62 (63.9)
7 (53.8)
16 (55.2)
27 (81.8)
12 (54.5)
-Poor
35 (36.1)
6 (46.2)
13 (44.8)
6 (18.2)
10 (45.5)
Lauren classification
0.003
-Intestinal
65 (67.1)
11 (84.6)
12 (41.4)
27 (81.8)
15 (68.2)
-Diffuse/mixed
32 (32.9)
2 (15.4)
17 (58.6)
6 (18.2)
7 (31.8)
HER2 immunostaining
0.874
-Positive
9 (9.3)
1 (7.7)
2 (6.9)
3 (9.1)
3 (13.6)
-Negative
88 (90.7)
12 (92.3)
27 (93.1)
30 (90.9)
19 (86.4)
EBV
0.296
-Positive
6 (6.2)
0 (0)
1 (3.4)
2 (6.1)
3 (13.6)
-Negative
91 (93.8)
13 (100)
28 (96.6)
31 (93.9)
19 (86.4)
PD-L1 immunostaining
0.418
-Positive
6 (15.8)
3 (50)
1 (9.1)
1 (9.1)
1 (10)
-Negative
32 (84.2)
3 (50)
10 (90.9)
10 (90.9)
9 (90)
MSI: microsatellite instability; MSS/EMT: microsatellite stable with epithelial-to-mesenchymal transition; MSS/p53-: microsatellite stable with inactive p53; MSS/p53+: microsatellite stable with active p53; previously reported [13].
